Figure 1
From: Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
Trial design of ongoing randomised neoadjuvant studies targeting HER2 with new agents. *Only the randomization for HER2 positive patients is presented. AC, doxorubicin-cyclophosphamide; EC, epirubicin-cyclophosphamide; FEC, 5-fluoruracil-epirubicin-cyclophosphamide; H, trastuzumab; HER2, human epidermal growth factor receptor 2; L, lapatinib; letro, letrozole; NR, not reported; p, paclitaxel; R, randomisation, T, docetaxel; X, capecitabine.